Bremelanotide
Definition: The clinical, FDA-approved pharmaceutical formulation of PT-141 used to treat Hypoactive Sexual Desire Disorder (HSDD).
What is Bremelanotide?
Bremelanotide is the official, clinically approved pharmaceutical name for the peptide widely known in research as PT-141. It is a synthetic peptide analog of alpha-Melanocyte Stimulating Hormone (α-MSH). Developed as a targeted prescription drug, it is the first and only FDA-approved subcutaneous peptide therapy specifically designed to address low sexual desire in premenopausal women.
How does Bremelanotide work?
Bremelanotide functions as a melanocortin receptor agonist, selectively binding to MC3 and MC4 receptors in the central nervous system. By activating these receptors in the brain, it modulates neural pathways in the hypothalamus that control sexual motivation, excitement, and subjective arousal. It acts independently of local vascular pathways, distinguishing it from vasoactive erectile dysfunction medications.
Primary Documented Uses
- Clinical treatment of generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women (Vyleesi)
- On-demand treatment for sexual arousal dysfunction
Research Summary
Two large-scale, double-blind, placebo-controlled Phase 3 clinical trials (RECONNECT) established Bremelanotide's efficacy. Premenopausal women using Bremelanotide experienced statistically significant increases in sexual desire and reductions in distress associated with low libido. Common side effects include temporary nausea (which can be managed), flushing, and a transient increase in blood pressure that resolves within hours.
Legal and Regulatory Status
Bremelanotide is fully FDA-approved under the brand name Vyleesi. It is a prescription-only medication and must be administered via an autoinjector subcutaneously at least 45 minutes before anticipated sexual activity. Compounded variants are legally prepared by compounding pharmacies under prescription.
Frequently Asked Questions
What is Bremelanotide?
Bremelanotide is The clinical, FDA-approved pharmaceutical formulation of PT-141 used to treat Hypoactive Sexual Desire Disorder (HSDD).
How does Bremelanotide work?
Bremelanotide functions as a melanocortin receptor agonist, selectively binding to MC3 and MC4 receptors in the central nervous system. By activating these receptors in the brain, it modulates neural pathways in the hypothalamus that control sexual motivation, excitement, and subjective arousal. It acts independently of local vascular pathways, distinguishing it from vasoactive erectile dysfunction medications.
What does research say about Bremelanotide?
Two large-scale, double-blind, placebo-controlled Phase 3 clinical trials (RECONNECT) established Bremelanotide's efficacy. Premenopausal women using Bremelanotide experienced statistically significant increases in sexual desire and reductions in distress associated with low libido. Common side effects include temporary nausea (which can be managed), flushing, and a transient increase in blood pressure that resolves within hours.
Is Bremelanotide FDA-approved or legally available?
Bremelanotide is fully FDA-approved under the brand name Vyleesi. It is a prescription-only medication and must be administered via an autoinjector subcutaneously at least 45 minutes before anticipated sexual activity. Compounded variants are legally prepared by compounding pharmacies under prescription.